GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abivax SA (STU:2X1) » Definitions » Net Income From Continuing Operations

Abivax (STU:2X1) Net Income From Continuing Operations : €-147.74 Mil (TTM As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Abivax Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Abivax's net income from continuing operations for the six months ended in Dec. 2023 was €-126.56 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2023 was €-147.74 Mil.

Abivax Net Income From Continuing Operations Historical Data

The historical data trend for Abivax's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abivax Net Income From Continuing Operations Chart

Abivax Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income From Continuing Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only -33.30 -38.01 -42.45 -60.74 -147.74

Abivax Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -25.56 -51.95 -8.79 -21.18 -126.56

Abivax Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-147.74 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Abivax Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abivax SA (STU:2X1) » Definitions » Net Income From Continuing Operations
Comparable Companies
XPAR:VLA XPAR:NANO XPAR:DBV XPAR:IPH XPAR:IVA XPAR:AELIS XPAR:MEDCL XPAR:GNFT XPAR:TNG XPAR:ALSEN OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
ABVX:USA 0RA9:UK ABVX:France
Address
7-11 boulevard Haussmann, Paris, FRA, 75009
Website
https://www.abivax.com
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. They are evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two most common forms are UC and CD.

Abivax Headlines

No Headlines